secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001558370-23-001826
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025
--------------------------------------------------------------------------------

- Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.
- Q4 total revenue $7.8M (incl. $6.7M licensing, $5M from Pediatrix) vs $1.5M prior year.
- Cash, equivalents and marketable securities $229.8M; expected to fund operations through end of 2025.
- Phase 2a zunsemetinib HS topline data expected March 2023; Phase 2b RA data H2 2023.
- Phase 2b ATI-1777 atopic dermatitis topline data mid-2023; Phase 1 MAD ATI-2138 data H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/0001558370-23-001826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/acrs-20230223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer